The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.
Abstract
Following oral administration of [14C]-gefitinib to albino and pigmented rats, radioactivity was widely and rapidly distributed, with the highest levels being found in liver, kidney, lung and gastrointestinal tract, but with only low levels penetrating the brain. Levels of radioactivity persisted in melanin-containing tissues (pigmented eye and skin). Binding to plasma proteins was high (86-94%) across the range of species examined and was 91% in human plasma. Substantial binding occurred to both human serum albumin and alpha-1 acid glycoprotein. Following oral and intravenous administration of [14C]-gefitinib, excretion of radioactivity by rat, dog and human occurred predominantly via the bile into faeces, with < 7% of the dose being eliminated in urine. In all three species, gefitinib was cleared primarily by metabolism. In rat, morpholine ring oxidation was the major route of metabolism, leading to the formation of M537194 and M608236 as the main biliary metabolites. Morpholine ring oxidation, together with production of M523595 by O-demethylation of the quinazoline moiety, were the predominant pathways in dog, with oxidative defluorination also occurring to a lesser degree. Pathways in healthy human volunteers were similar to dog, with O-demethylation and morpholine ring oxidation representing the major routes of metabolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The existence of cell populations harboring T790M within a proportion of TKI-naïve EGFRm+ tumors has been reported, although the prevalence depends on the diagnostic assay being used.”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [58]
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,796
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Fiore, P. P. D., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,011
Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., & Gibson, K. H. (2002) · PubMed · doi:10.7270/q2pc374f · Cited by 925
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 834
Ranson, M., Hammond, L. A., Ferry, D. K., Kris, M. G., Tullo, A. B., Murray, P. I., Miller, V. A., Averbuch, S. D., Ochs, J., Morris, C. Q., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 764
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Drug binding to human alpha-1-acid glycoprotein in health and disease.
Kremer, J. M., Wilting, J., & Janssen, L. H. M. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00015-8 · Cited by 584
Herbst, R. S., Maddox, A., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J. M., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572
Role of transport proteins in drug absorption, distribution and excretion
Ayrton, A. D., & Morgan, P. M. (2001) · Xenobiotica · doi:10.1080/00498250110060969 · Cited by 426
Sainsbury, J. R. C., Malcolm, A. J., Appleton, D. R., Farndon, J. R., & Harris, A. L. (1985) · Journal of Clinical Pathology · doi:10.1136/jcp.38.11.1225 · Cited by 226
Binding of Drugs to Eye Melanin Is Not Predictive of Ocular Toxicity
Leblanc, B., Jezequel, S. G., Davies, T., Hanton, G. C., & Taradach, C. (1998) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1998.1243 · Cited by 179
Heimberger, A. B., Learn, C. A., Archer, G. E., McLendon, R. E., Chewning, T. A., Tuck, F. L., Pracyk, J. B., Friedman, A. H., Friedman, H. S., Bigner, D. D., et al. (2002) · PubMed · Cited by 169
Drug Metabolism and Disposition
Silva, M. F. B., IJlst, L., Allers, P., Jakobs, C., Durán, M., de Almeida, I. T., & Wanders, R. J. A. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd · Cited by 125
Anti-epidermal growth factor receptor drugs in cancer therapy
Tortora, G., & Ciardiello, F. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.6.755 · Cited by 101
Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide*
Mayersohn, M., & Guentert, T. W. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529050-00002 · Cited by 61
A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain
Villano, J. L., Mauer, A. M., & Vokes, E. E. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg153 · Cited by 51
McKillop, D., Partridge, E. A., Hutchison, M., Rhead, S., Parry, A. C., Bardsley, J., Woodman, H. M., & Swaisland, H. (2004) · Xenobiotica · doi:10.1080/00498250400009189 · Cited by 46
Workman, P., Brunton, V. G., & ROBINS, D. J. (2012) · SpringerReference · doi:10.1007/springerreference_138029 · Cited by 35
Timolol metabolism in man and laboratory anamals.
Tocco, D. J., Duncan, A. E., Deluna, F. A., Smith, J. L., Walker, R. W., & VandenHeuvel, W. J. A. (1980) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)00263-6 · Cited by 23
Mutch, P. J., Dear, G. J., & Ismail, I. M. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011775479 · Cited by 18
New targets for therapeutic attack
Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., & Woodburn, J. R. (1997) · Endocrine Related Cancer · doi:10.1677/erc.0.0040351 · Cited by 14
McKillop, D., Raab, G., Eidtmann, H., Furnival, A., Riva, A., Forbes, J., Mackey, J., Spence, M. P., Koehler, M. T., & Slamon, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.581 · Cited by 12
Denissen, J. F., Grabowski, B. A., Johnson, M. K., Boyd, S. A., Uchic, J. T., Stein, H. H., Cepa, S. P., & Hill, P. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08431-4 · Cited by 12
Disposition and metabolism of indeloxazine hydrochloride, a cerebral activator, in rats
Kamimura, H., Enjoji, Y., Sasaki, H., Kawai, R., Kaniwa, H., NIIGATA, K., & Kageyama, S. (1987) · Xenobiotica · doi:10.3109/00498258709043972 · Cited by 9
Metabolism of the aldose reductase inhibitor ALO1567 in man.
Park, Y., Hudson, J. L., Barker, R., York, B. M., & Brazzell, R. K. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03885.x · Cited by 6
Research works printed but not linked: 3
- HEIMBERGER A. B., 2002, Clinical Cancer Research, 8, 3496
- WAKELING A. E., 2002, Cancer Research, 62, 5749
- WORKMAN P., 1992, Seminars in Cancer Biology, 3, 369
Cited by
Sorted by citations
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes
Li, J., Zhao, M., He, P., Hidalgo, M. M., & Baker, S. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0088 · Cited by 310
Kourounakis, A. P., Xanthopoulos, D., & Tzara, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21634 · Cited by 314
Metadata
- Authors
- McKillop, D., Hutchison, M., Partridge, E. A., Bushby, N., Cooper, C. M. F., Clarkson-Jones, J. A., Herron, W., & Swaisland, H. C.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- IQVIA (United Kingdom) (GB)
- Corresponding author
- McKillop, D.
- ORCID
- Bushby, N.
- Venue
- Xenobiotica
- Publisher
- Informa UK Limited
- Published
- 2004-10
- Volume
- 34
- Issue
- 10
- Pages
- 917-934
- ISSN
- 0049-8254 (ISSN-L)
- 1366-5928
- OpenAlex
- W2063306919
- Cited by
- 130
- References
- 28
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 3 · 2017: 5 · 2016: 10 · 2015: 8 · 2014: 7 · 2013: 9 · 2012: 5
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Xenobiotica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- gefitinib, metabolic disposition, epidermal growth factor receptor tyrosine kinase inhibitors, O-demethylation, oxidative defluorination, biliary excretion, plasma protein binding, human serum albumin, alpha-1-acid glycoprotein, species comparison, drug metabolism, biliary metabolites
- MeSH terms
- Gefitinib, Administration, Oral, Animals, Antineoplastic Agents, Dogs, Drug Evaluation, Preclinical, Female, Humans, Male, Metabolic Clearance Rate, Organ Specificity, Protein-Tyrosine Kinases, Quinazolines, Sex Factors, Species Specificity, Tissue Distribution, Rats, Sprague-Dawley, Rats, Wistar, Protein Kinase Inhibitors, Rats, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
